Febuxostat (uloric), a new treatment option for gout

P and T

Volumn 35, Issue 2, 2010, Pages 82-85

  Avena Woods, Carmela ^a   Hilas, Olga ^a,b  

^a ST JOHN'S UNIVERSITY   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ALUMINUM HYDROXIDE; ANTACID AGENT; AZATHIOPRINE; COLCHICINE; DESIPRAMINE; FEBUXOSTAT; HYDROCHLOROTHIAZIDE; INDOMETACIN; MAGNESIUM; MERCAPTOPURINE; NAPROXEN; PLACEBO; THEOPHYLLINE; ULORIC; UNCLASSIFIED DRUG; URATE; URIC ACID; WARFARIN;

ARTHRALGIA; ARTHROPATHY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMPETITIVE INHIBITION; CONNECTIVE TISSUE DISEASE; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG COST; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; GOUT; HUMAN; HYPERURICEMIA; LIVER FUNCTION; MOLECULAR WEIGHT; MUSCULOSKELETAL DISEASE; NAUSEA; RASH; REVIEW; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URIC ACID BLOOD LEVEL;

EID: 77954375974     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Wortmann RL. Disorders of purine and pyrimidine metabolism (chapter 353). In: Fauci AS, Braunwald E, Kasper DL, et al. Harrison's Principles of Internal Medicine, 17th ed. New York: McGraw-Hill; 2008: 2444. Available at: www.accessmedicine. com/content.aspx?aid=2882696. Accessed January 11, 2010.
2. Pittman JR, Bross MH. Diagnosis and management of gout. Am Fam Physician 1999;599(7):1799-1806.
3. Loeb JN. The influence of temperature on the solubility of monosodium urate. Arthritis Rheum 1972;15:189-192.
4. Becker MA, Schumacher HR, Wortmann RL, et al. Febuxostat, a novel nonpurine inhibitor of xanthine oxidase. Arthritis Rheum 2005;52(3):916-923.
5. Hall AP, Barry PE, Dawber PR, et al. Epidemiology of gout and hyperuricemia: A long-term population study. Am J Med 1967;42:27-37.
6. Eggebeen AT. Gout: An update. Am Fam Physician 2007;76(6):801-808.
7. Rott KT, Agudelo CA. Gout. JAMA 2003;289(21):2857-2860.
8. Harris, MD, Siegel LB, Alloway JA. Gout and hyperuricemia. Am Fam Physician 1999;59(4):925-934.
9. Keith MP, Gilliland WR. Updates in the management of gout. Am J Med 2007; 120(3):221-224.
10. Zbang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout: Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312-1324. (Pubitemid 44620440)
11. Kelley WN, Schumacher HR Jr. Crystal- associated synovitis. In: Kelley WN, ed. Textbook of Rheumatology, 4th ed. Philadelphia: WB Saunders; 1993:1291-1336.
12. Uloric (febuxostat), prescribing information. Deerfield, IL: Takeda, Inc.; February 2009.
13. FDA. FDA approves drug for gout management. February 13, 2009. Available at: www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/ucm1 49534.htm. Accessed January 11, 2010.
14. Bruce SP. Febuxostat: A selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout. Ann Pharmacother 2006;40:2187-2194. (Pubitemid 44954438)
15. Febuxostat (Uloric) for chronic treatment of gout. Med Lett Drugs Ther 2009; 51(1312):37-38.
16. Okamoto K, Eger BT, Nishino T, et al. An extremely potent inhibitor of xanthine oxidoreductase: Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition. J Biol Chem 2003;278:1848-1855. (Pubitemid 36801423)
17. Takano Y, Hase-Aoki K, Horiuchi H, et al. Selectivity of febuxostat, a novel non- purine inhibitor of xanthine oxidase/ xanthine dehydrogenase. Life Sci 2005; 76:1835-1847. (Pubitemid 40215224)
18. Khosravan K, Grabowski B, Wu JT, et al. Effect of food or antacid on pharmaco- kinetics and pharmacodynamics of febuxostat in healthy subjects. Br J Gun Pharmacol 2007;65(3):355-363. (Pubitemid 351316909)
19. Khosravan R, Grabowski BA, Wu J, et al. Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects. 2006;45(8):821-841.
20. Becker MA, Schumacher HR, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005;353(23): 2450-2461.
21. Schumacher HR, Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: A 28-week, phase Ill, randomized, double-blind, parallel group trial. Arthritis Rheum 2008;59(11):1540-1548.
22. Becker MA, Schumacher HR, Espinoza L, et al. A phase 3 randomized, controlled, multicenter, double-blind trial (RCT) comparing efficacy and safety of daily febuxostat (FEB) and allopurinol (ALLO) in subjects with gout. Presented at the 2008 Annual Scientific Meeting of the American College of Rheumatology, San Francisco, October 24-29, 2008. Available at: http://acr.confex.com/acr/2008/ webprogram/Paper3414.html. Accessed January 11, 2010.
23. Uloric (febuxostat). Red Book, 113th ed. Thomson Healthcare; August 2009 Supplement, p65.